Naoka Murakami, M.D., Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Kidney Transplantation | 19 | 2024 | 4251 | 2.940 |
Why?
|
Facial Transplantation | 4 | 2023 | 226 | 1.120 |
Why?
|
Kidney Failure, Chronic | 4 | 2023 | 2538 | 0.960 |
Why?
|
Graft Rejection | 13 | 2023 | 4397 | 0.860 |
Why?
|
Acute Kidney Injury | 5 | 2022 | 1972 | 0.620 |
Why?
|
Glomerulonephritis, Membranous | 1 | 2018 | 86 | 0.600 |
Why?
|
Interleukin-2 | 2 | 2023 | 1904 | 0.570 |
Why?
|
Hospice Care | 1 | 2023 | 672 | 0.560 |
Why?
|
Tissue and Organ Procurement | 2 | 2022 | 896 | 0.510 |
Why?
|
Receptors, Notch | 1 | 2020 | 739 | 0.510 |
Why?
|
T-Lymphocytes, Regulatory | 5 | 2023 | 2988 | 0.510 |
Why?
|
Civil Defense | 1 | 2015 | 109 | 0.460 |
Why?
|
Cyclonic Storms | 1 | 2015 | 119 | 0.460 |
Why?
|
Immunomodulation | 1 | 2016 | 541 | 0.430 |
Why?
|
Renin | 1 | 2015 | 642 | 0.430 |
Why?
|
Organ Transplantation | 2 | 2022 | 1139 | 0.420 |
Why?
|
Receptors, G-Protein-Coupled | 3 | 2014 | 1222 | 0.420 |
Why?
|
Multiple Endocrine Neoplasia Type 1 | 1 | 2012 | 46 | 0.420 |
Why?
|
Autoimmunity | 2 | 2024 | 1349 | 0.410 |
Why?
|
Hyperaldosteronism | 1 | 2015 | 240 | 0.400 |
Why?
|
Terminal Care | 1 | 2023 | 1694 | 0.400 |
Why?
|
Pharyngeal Diseases | 1 | 2012 | 133 | 0.390 |
Why?
|
Renal Dialysis | 2 | 2023 | 1786 | 0.390 |
Why?
|
Immunosuppressive Agents | 4 | 2022 | 4149 | 0.380 |
Why?
|
Carcinoma, Squamous Cell | 3 | 2024 | 4034 | 0.380 |
Why?
|
Core Binding Factor Alpha 2 Subunit | 2 | 2010 | 345 | 0.380 |
Why?
|
Choristoma | 1 | 2012 | 213 | 0.370 |
Why?
|
Parathyroid Glands | 1 | 2012 | 509 | 0.370 |
Why?
|
Immune Tolerance | 3 | 2019 | 2258 | 0.370 |
Why?
|
Lysophosphatidylcholines | 3 | 2014 | 81 | 0.360 |
Why?
|
Hyperparathyroidism, Primary | 1 | 2012 | 160 | 0.360 |
Why?
|
Antiviral Agents | 2 | 2022 | 2987 | 0.360 |
Why?
|
Hepatitis C, Chronic | 1 | 2018 | 1031 | 0.360 |
Why?
|
Aldosterone | 1 | 2015 | 877 | 0.350 |
Why?
|
CCAAT-Enhancer-Binding Protein-beta | 1 | 2009 | 103 | 0.350 |
Why?
|
Multiple Myeloma | 3 | 2022 | 5181 | 0.340 |
Why?
|
Disasters | 1 | 2015 | 511 | 0.340 |
Why?
|
Renal Insufficiency, Chronic | 1 | 2023 | 2208 | 0.340 |
Why?
|
Anesthetics | 1 | 2015 | 539 | 0.330 |
Why?
|
Macrophages, Peritoneal | 1 | 2009 | 251 | 0.330 |
Why?
|
T-Lymphocytes | 6 | 2021 | 10180 | 0.320 |
Why?
|
Shock, Septic | 1 | 2015 | 775 | 0.310 |
Why?
|
Neoplasms | 3 | 2023 | 21683 | 0.300 |
Why?
|
Delivery of Health Care, Integrated | 1 | 2015 | 941 | 0.290 |
Why?
|
Cell Cycle Proteins | 2 | 2009 | 3462 | 0.270 |
Why?
|
Kidney Diseases | 1 | 2016 | 2149 | 0.260 |
Why?
|
Immunity, Humoral | 2 | 2022 | 598 | 0.260 |
Why?
|
Skin Neoplasms | 2 | 2024 | 5686 | 0.260 |
Why?
|
TOR Serine-Threonine Kinases | 1 | 2014 | 2109 | 0.250 |
Why?
|
Phosphorylcholine | 1 | 2004 | 162 | 0.240 |
Why?
|
Cerebral Hemorrhage | 1 | 2015 | 2647 | 0.220 |
Why?
|
Humans | 49 | 2024 | 744343 | 0.220 |
Why?
|
CD4-Positive T-Lymphocytes | 1 | 2016 | 4386 | 0.220 |
Why?
|
Nephritis, Interstitial | 2 | 2021 | 156 | 0.220 |
Why?
|
Antibodies, Monoclonal | 2 | 2017 | 9274 | 0.220 |
Why?
|
Isoantibodies | 2 | 2023 | 679 | 0.210 |
Why?
|
Sphingosine | 1 | 2004 | 307 | 0.210 |
Why?
|
Sepsis | 1 | 2015 | 2593 | 0.190 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2015 | 3923 | 0.190 |
Why?
|
Kidney | 5 | 2023 | 7186 | 0.180 |
Why?
|
Monocytes | 1 | 2009 | 2596 | 0.180 |
Why?
|
Trans-Activators | 1 | 2009 | 2924 | 0.180 |
Why?
|
Nephrology | 1 | 2023 | 263 | 0.170 |
Why?
|
Antineoplastic Agents | 3 | 2017 | 13695 | 0.170 |
Why?
|
Signal Transduction | 6 | 2020 | 23403 | 0.170 |
Why?
|
Diet, Gluten-Free | 1 | 2021 | 271 | 0.160 |
Why?
|
Integrin alpha Chains | 1 | 2018 | 97 | 0.160 |
Why?
|
Adrenal Cortex Hormones | 3 | 2024 | 1855 | 0.160 |
Why?
|
Uridine Monophosphate | 1 | 2018 | 70 | 0.160 |
Why?
|
Health Services Accessibility | 1 | 2015 | 5137 | 0.160 |
Why?
|
Receptor, Interferon alpha-beta | 1 | 2018 | 107 | 0.160 |
Why?
|
Antilymphocyte Serum | 2 | 2022 | 492 | 0.150 |
Why?
|
Palliative Care | 2 | 2023 | 3493 | 0.150 |
Why?
|
Glomerular Filtration Rate | 2 | 2023 | 2170 | 0.150 |
Why?
|
Dairy Products | 1 | 2021 | 498 | 0.150 |
Why?
|
Glomerulonephritis, IGA | 1 | 2017 | 66 | 0.150 |
Why?
|
Nephrotic Syndrome | 1 | 2021 | 389 | 0.150 |
Why?
|
Fluorenes | 1 | 2018 | 160 | 0.150 |
Why?
|
Proto-Oncogene Proteins | 1 | 2009 | 4554 | 0.150 |
Why?
|
Specialization | 1 | 2022 | 777 | 0.150 |
Why?
|
Histocompatibility Antigens Class I | 1 | 2023 | 1366 | 0.140 |
Why?
|
Receptor, Notch1 | 1 | 2019 | 502 | 0.140 |
Why?
|
Amyloidosis | 1 | 2022 | 795 | 0.130 |
Why?
|
Graft Survival | 4 | 2022 | 3737 | 0.130 |
Why?
|
Receptors, Antigen, T-Cell | 2 | 2023 | 2540 | 0.130 |
Why?
|
Antigen Presentation | 1 | 2021 | 1284 | 0.130 |
Why?
|
Gene Expression Profiling | 2 | 2021 | 9438 | 0.130 |
Why?
|
Pilot Projects | 3 | 2023 | 8324 | 0.120 |
Why?
|
Vitamins | 1 | 2022 | 1622 | 0.120 |
Why?
|
Immunity, Cellular | 2 | 2016 | 1607 | 0.110 |
Why?
|
New York City | 1 | 2015 | 710 | 0.110 |
Why?
|
Benzimidazoles | 1 | 2018 | 850 | 0.110 |
Why?
|
Ligands | 2 | 2014 | 3282 | 0.110 |
Why?
|
Gene Expression Regulation | 2 | 2019 | 12072 | 0.110 |
Why?
|
Pyriform Sinus | 1 | 2012 | 7 | 0.110 |
Why?
|
Pre-Eclampsia | 1 | 2022 | 1200 | 0.110 |
Why?
|
Neoplasms, Experimental | 1 | 2018 | 1276 | 0.110 |
Why?
|
Electrophoretic Mobility Shift Assay | 2 | 2010 | 300 | 0.110 |
Why?
|
Stroke | 1 | 2015 | 9981 | 0.100 |
Why?
|
Autoimmune Diseases | 1 | 2024 | 2133 | 0.100 |
Why?
|
Models, Organizational | 1 | 2015 | 574 | 0.100 |
Why?
|
Opportunistic Infections | 1 | 2014 | 389 | 0.100 |
Why?
|
Proteasome Endopeptidase Complex | 1 | 2017 | 1338 | 0.100 |
Why?
|
Awareness | 1 | 2015 | 640 | 0.100 |
Why?
|
T-Lymphocyte Subsets | 1 | 2019 | 1838 | 0.100 |
Why?
|
Th1 Cells | 1 | 2016 | 1057 | 0.100 |
Why?
|
Hepacivirus | 1 | 2018 | 1379 | 0.100 |
Why?
|
Drug Resistance | 1 | 2016 | 1609 | 0.090 |
Why?
|
Biopsy | 2 | 2021 | 6756 | 0.090 |
Why?
|
Chromatin Immunoprecipitation | 2 | 2010 | 893 | 0.090 |
Why?
|
Premature Birth | 1 | 2022 | 1721 | 0.090 |
Why?
|
Withholding Treatment | 1 | 2014 | 599 | 0.090 |
Why?
|
Interleukin-17 | 1 | 2016 | 899 | 0.090 |
Why?
|
Receptors, Leukotriene B4 | 1 | 2010 | 94 | 0.090 |
Why?
|
Fluorescent Antibody Technique | 1 | 2014 | 2505 | 0.090 |
Why?
|
Lipids | 1 | 2021 | 3305 | 0.090 |
Why?
|
Early Diagnosis | 1 | 2015 | 1184 | 0.090 |
Why?
|
Lymphocytes | 1 | 2017 | 2617 | 0.090 |
Why?
|
Immunophenotyping | 1 | 2014 | 1880 | 0.090 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2023 | 4479 | 0.090 |
Why?
|
Transcription Initiation Site | 1 | 2009 | 196 | 0.080 |
Why?
|
Blotting, Southern | 1 | 2009 | 803 | 0.080 |
Why?
|
Steroids | 1 | 2014 | 930 | 0.080 |
Why?
|
Ubiquitin-Protein Ligases | 1 | 2018 | 1861 | 0.080 |
Why?
|
Immunotherapy | 2 | 2021 | 4445 | 0.080 |
Why?
|
Chi-Square Distribution | 1 | 2015 | 3508 | 0.080 |
Why?
|
Heart Transplantation | 1 | 2021 | 3110 | 0.080 |
Why?
|
Antibodies, Blocking | 2 | 2019 | 253 | 0.080 |
Why?
|
Checklist | 1 | 2015 | 833 | 0.080 |
Why?
|
Blotting, Northern | 1 | 2009 | 1581 | 0.080 |
Why?
|
Health Care Surveys | 1 | 2015 | 2453 | 0.080 |
Why?
|
Antigens, CD | 1 | 2018 | 4026 | 0.080 |
Why?
|
Antigens | 2 | 2024 | 1466 | 0.080 |
Why?
|
Animals | 10 | 2022 | 168757 | 0.080 |
Why?
|
Hypercholesterolemia | 1 | 2014 | 1151 | 0.080 |
Why?
|
Skin | 1 | 2021 | 4364 | 0.080 |
Why?
|
Interferon-gamma | 1 | 2016 | 3206 | 0.070 |
Why?
|
T-Lymphocytes, Helper-Inducer | 2 | 2024 | 986 | 0.070 |
Why?
|
Dendritic Cells | 1 | 2018 | 2725 | 0.070 |
Why?
|
HLA Antigens | 2 | 2023 | 1381 | 0.070 |
Why?
|
Anti-Infective Agents | 1 | 2014 | 972 | 0.070 |
Why?
|
Treatment Outcome | 4 | 2023 | 63114 | 0.070 |
Why?
|
Recurrence | 1 | 2018 | 8340 | 0.070 |
Why?
|
Fluorescent Dyes | 1 | 2014 | 1917 | 0.070 |
Why?
|
Lung Neoplasms | 2 | 2022 | 13102 | 0.070 |
Why?
|
Neoplasm Proteins | 1 | 2018 | 3703 | 0.070 |
Why?
|
Hydrogen-Ion Concentration | 2 | 2014 | 2557 | 0.060 |
Why?
|
Immunity, Innate | 1 | 2016 | 2958 | 0.060 |
Why?
|
Cell Membrane | 1 | 2014 | 3748 | 0.060 |
Why?
|
Inositol Phosphates | 1 | 2004 | 180 | 0.060 |
Why?
|
Male | 13 | 2021 | 350118 | 0.060 |
Why?
|
PC12 Cells | 1 | 2004 | 330 | 0.060 |
Why?
|
Microscopy, Confocal | 2 | 2014 | 1970 | 0.060 |
Why?
|
Time Factors | 4 | 2021 | 40075 | 0.060 |
Why?
|
Histidine | 1 | 2004 | 313 | 0.060 |
Why?
|
Homeostasis | 1 | 2014 | 3340 | 0.060 |
Why?
|
Aged | 7 | 2021 | 163280 | 0.050 |
Why?
|
Odds Ratio | 1 | 2015 | 9849 | 0.050 |
Why?
|
NIH 3T3 Cells | 1 | 2004 | 677 | 0.050 |
Why?
|
Pandemics | 1 | 2022 | 8388 | 0.050 |
Why?
|
HLA-A2 Antigen | 1 | 2022 | 213 | 0.050 |
Why?
|
COS Cells | 1 | 2004 | 1161 | 0.050 |
Why?
|
Cell Proliferation | 1 | 2018 | 10481 | 0.050 |
Why?
|
Prospective Studies | 3 | 2021 | 53288 | 0.050 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2009 | 4751 | 0.050 |
Why?
|
Hypertension | 1 | 2022 | 8480 | 0.050 |
Why?
|
Delayed Graft Function | 1 | 2022 | 48 | 0.050 |
Why?
|
Leukocytes | 1 | 2010 | 2043 | 0.050 |
Why?
|
Immunoprecipitation | 1 | 2004 | 905 | 0.050 |
Why?
|
Cells, Cultured | 3 | 2019 | 19229 | 0.050 |
Why?
|
Peptide Fragments | 1 | 2014 | 5097 | 0.050 |
Why?
|
Multivariate Analysis | 1 | 2015 | 12245 | 0.050 |
Why?
|
Attitude of Health Personnel | 1 | 2015 | 3843 | 0.050 |
Why?
|
Histocompatibility Testing | 1 | 2023 | 741 | 0.050 |
Why?
|
Mutagenesis, Site-Directed | 1 | 2004 | 1723 | 0.050 |
Why?
|
Risk Factors | 5 | 2022 | 72290 | 0.050 |
Why?
|
Retrospective Studies | 4 | 2022 | 77449 | 0.050 |
Why?
|
Middle Aged | 8 | 2021 | 213383 | 0.050 |
Why?
|
Genes, Reporter | 1 | 2004 | 1547 | 0.050 |
Why?
|
Cell Line | 3 | 2018 | 15997 | 0.040 |
Why?
|
Sequence Homology, Amino Acid | 1 | 2004 | 2839 | 0.040 |
Why?
|
Mice, Inbred BALB C | 2 | 2019 | 6386 | 0.040 |
Why?
|
Mice | 6 | 2022 | 81183 | 0.040 |
Why?
|
Female | 11 | 2022 | 380194 | 0.040 |
Why?
|
Clone Cells | 1 | 2023 | 1692 | 0.040 |
Why?
|
Germinal Center | 1 | 2022 | 377 | 0.040 |
Why?
|
Postoperative Complications | 1 | 2021 | 15295 | 0.040 |
Why?
|
Protons | 1 | 2004 | 1127 | 0.040 |
Why?
|
STAT5 Transcription Factor | 1 | 2019 | 259 | 0.040 |
Why?
|
Methylprednisolone | 1 | 2020 | 387 | 0.040 |
Why?
|
Virulence | 1 | 2022 | 1333 | 0.040 |
Why?
|
United States | 2 | 2023 | 69872 | 0.040 |
Why?
|
Cloning, Molecular | 1 | 2004 | 4320 | 0.040 |
Why?
|
Anastomosis, Surgical | 1 | 2022 | 987 | 0.040 |
Why?
|
Age Factors | 1 | 2015 | 18370 | 0.040 |
Why?
|
Living Donors | 1 | 2022 | 620 | 0.040 |
Why?
|
Basic-Leucine Zipper Transcription Factors | 1 | 2018 | 154 | 0.040 |
Why?
|
Asparagine | 1 | 2017 | 122 | 0.040 |
Why?
|
B-Lymphocytes | 2 | 2024 | 4665 | 0.040 |
Why?
|
Survival Analysis | 2 | 2021 | 10252 | 0.040 |
Why?
|
Practice Guidelines as Topic | 1 | 2015 | 7279 | 0.040 |
Why?
|
Static Electricity | 1 | 2017 | 267 | 0.040 |
Why?
|
Severity of Illness Index | 1 | 2015 | 15540 | 0.040 |
Why?
|
Creatinine | 1 | 2022 | 1919 | 0.040 |
Why?
|
Antibodies, Neoplasm | 1 | 2018 | 286 | 0.040 |
Why?
|
Actins | 1 | 2004 | 2121 | 0.040 |
Why?
|
Transfection | 1 | 2004 | 5892 | 0.030 |
Why?
|
Molecular Sequence Data | 2 | 2010 | 18111 | 0.030 |
Why?
|
Prednisone | 1 | 2020 | 1574 | 0.030 |
Why?
|
Proteinuria | 1 | 2017 | 658 | 0.030 |
Why?
|
Th17 Cells | 1 | 2021 | 766 | 0.030 |
Why?
|
Cryoelectron Microscopy | 1 | 2017 | 571 | 0.030 |
Why?
|
RNA, Messenger | 1 | 2009 | 13033 | 0.030 |
Why?
|
Cross-Sectional Studies | 1 | 2015 | 25043 | 0.030 |
Why?
|
STAT3 Transcription Factor | 1 | 2018 | 873 | 0.030 |
Why?
|
Protein Subunits | 1 | 2017 | 959 | 0.030 |
Why?
|
Adult | 5 | 2023 | 214055 | 0.030 |
Why?
|
Aminoacyltransferases | 1 | 2014 | 51 | 0.030 |
Why?
|
Histocompatibility Antigens Class II | 1 | 2018 | 1475 | 0.030 |
Why?
|
Kidney Function Tests | 1 | 2016 | 684 | 0.030 |
Why?
|
Flow Cytometry | 1 | 2004 | 5974 | 0.030 |
Why?
|
Risk Assessment | 1 | 2014 | 23338 | 0.030 |
Why?
|
Interleukin-10 | 1 | 2018 | 1200 | 0.030 |
Why?
|
Promoter Regions, Genetic | 1 | 2004 | 5867 | 0.030 |
Why?
|
Tissue Donors | 1 | 2022 | 2240 | 0.030 |
Why?
|
Mycophenolic Acid | 1 | 2014 | 343 | 0.030 |
Why?
|
Amino Acid Sequence | 1 | 2004 | 13815 | 0.030 |
Why?
|
Inflammation Mediators | 1 | 2021 | 1889 | 0.030 |
Why?
|
Alleles | 1 | 2023 | 6933 | 0.030 |
Why?
|
Intestines | 1 | 2021 | 1924 | 0.030 |
Why?
|
Pregnancy Outcome | 1 | 2022 | 2795 | 0.030 |
Why?
|
Cysteine Endopeptidases | 1 | 2014 | 563 | 0.020 |
Why?
|
Feasibility Studies | 1 | 2021 | 5078 | 0.020 |
Why?
|
Mice, Inbred C57BL | 2 | 2019 | 21827 | 0.020 |
Why?
|
Immunoglobulin G | 1 | 2022 | 4560 | 0.020 |
Why?
|
Tacrolimus | 1 | 2014 | 743 | 0.020 |
Why?
|
HL-60 Cells | 1 | 2010 | 365 | 0.020 |
Why?
|
Cohort Studies | 2 | 2022 | 40561 | 0.020 |
Why?
|
Leukocytes, Mononuclear | 1 | 2016 | 1836 | 0.020 |
Why?
|
Sequence Homology, Nucleic Acid | 1 | 2010 | 1085 | 0.020 |
Why?
|
Binding Sites | 1 | 2017 | 6114 | 0.020 |
Why?
|
Phagocytosis | 1 | 2014 | 1539 | 0.020 |
Why?
|
Protein Transport | 1 | 2014 | 1988 | 0.020 |
Why?
|
Transplantation, Homologous | 1 | 2016 | 4776 | 0.020 |
Why?
|
Rabbits | 1 | 2014 | 4894 | 0.020 |
Why?
|
Rats | 1 | 2004 | 24260 | 0.020 |
Why?
|
Models, Molecular | 1 | 2017 | 5456 | 0.020 |
Why?
|
Repressor Proteins | 1 | 2018 | 3023 | 0.020 |
Why?
|
Follow-Up Studies | 2 | 2021 | 39050 | 0.020 |
Why?
|
Mice, Transgenic | 1 | 2019 | 9734 | 0.020 |
Why?
|
Lymphocyte Activation | 1 | 2017 | 5524 | 0.020 |
Why?
|
Cytokines | 1 | 2021 | 7322 | 0.020 |
Why?
|
Acute Disease | 1 | 2016 | 7149 | 0.020 |
Why?
|
Chromatin Assembly and Disassembly | 1 | 2010 | 635 | 0.020 |
Why?
|
HEK293 Cells | 1 | 2014 | 4204 | 0.020 |
Why?
|
Child | 2 | 2022 | 77709 | 0.010 |
Why?
|
Enhancer Elements, Genetic | 1 | 2010 | 1341 | 0.010 |
Why?
|
Mice, Knockout | 1 | 2018 | 14557 | 0.010 |
Why?
|
Disease Models, Animal | 1 | 2021 | 18029 | 0.010 |
Why?
|
Blotting, Western | 1 | 2010 | 5179 | 0.010 |
Why?
|
Infant, Newborn | 1 | 2022 | 25625 | 0.010 |
Why?
|
Risk | 1 | 2014 | 9687 | 0.010 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2014 | 10943 | 0.010 |
Why?
|
Cost-Benefit Analysis | 1 | 2014 | 5391 | 0.010 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2022 | 11524 | 0.010 |
Why?
|
RNA Interference | 1 | 2010 | 2889 | 0.010 |
Why?
|
Cell Line, Tumor | 1 | 2017 | 16689 | 0.010 |
Why?
|
Bacterial Proteins | 1 | 2014 | 3848 | 0.010 |
Why?
|
Polymerase Chain Reaction | 1 | 2010 | 6171 | 0.010 |
Why?
|
Pregnancy | 1 | 2022 | 29144 | 0.010 |
Why?
|
Neoplasm Recurrence, Local | 1 | 2017 | 9239 | 0.010 |
Why?
|
Models, Statistical | 1 | 2014 | 5102 | 0.010 |
Why?
|
Infant | 1 | 2021 | 35136 | 0.010 |
Why?
|
Base Sequence | 1 | 2010 | 12797 | 0.010 |
Why?
|
Child, Preschool | 1 | 2021 | 41006 | 0.010 |
Why?
|
Protein Binding | 1 | 2010 | 9386 | 0.010 |
Why?
|
Image Processing, Computer-Assisted | 1 | 2014 | 8949 | 0.010 |
Why?
|
Prognosis | 1 | 2016 | 29063 | 0.010 |
Why?
|
Young Adult | 1 | 2021 | 56430 | 0.010 |
Why?
|
Adolescent | 1 | 2021 | 85781 | 0.010 |
Why?
|